Royalty Pharma plc (RPRX) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 10 Buy, 1 Hold.
The consensus price target is $51.25 (low: $45.00, high: $61.00), representing an upside of 5% from the current price $48.82.
Analysts estimate Earnings Per Share (EPS) of $4.05 and revenue of $2.69B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $1.92 vs est $4.05 (missed -52.6%). 2025: actual $2.33 vs est $4.63 (missed -49.7%). Analyst accuracy: 0%.
RPRX Stock — 12-Month Price Forecast
$51.25
▲ +4.98% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Royalty Pharma plc, the average price target is $51.25, with a high forecast of $61.00, and a low forecast of $45.00.
The average price target represents a +4.98% change from the last price of $48.82.
Highest Price Target
$61.00
Average Price Target
$51.25
Lowest Price Target
$45.00
RPRX Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Royalty Pharma plc in the past 3 months
EPS Estimates — RPRX
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $1.92
vs Est $4.05
▼ 110.9% off
2025
Actual $2.33
vs Est $4.63
▼ 98.8% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — RPRX
77%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $2.264B
vs Est $2.689B
▼ 18.8% off
2025
Actual $2.378B
vs Est $3.009B
▼ 26.5% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
